HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility

ConclusionAlthough this polymorphism did not demonstrate potential as a prognostic marker, it may be a suitable susceptibility marker for BC.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Tags: RESEARCH ARTICLE Source Type: research

Related Links:

Authors: Li L, Liu S, Liu L, Ma Z, Feng M, Ye C, Zhou W, Wang Y, Liu L, Wang F, Yu L, Zhou F, Xiang Y, Huang S, Fu Q, Zhang Q, Gao D, Yu Z Abstract The expression of insulin-like growth factor-1 receptor (IGF-1R), which is involved in the genesis and progression of breast cancer, is thought to be associated with the overall survival (OS) of patients. However, the predictive and prognostic significance of the IGF-1R expression in breast cancer remains controversial. The present study aimed to identify the factors associated with the levels of phosphorylated (p)-IGF-1R in breast cancer, their impact on the outcomes o...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
(Jackson Laboratory) IL1b, a member of the interleukin 1 family of cytokines (proteins released by certain cells of the immune system) drives the inflammation often found in cancer, and appears as an 'IL1 signature' in women with HER2-negative metastatic breast cancer. This signature can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Wang Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatmen...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Distribution and prognostic value of tumor‑infiltrating T cells in breast cancer. Mol Med Rep. 2018 Sep 05;: Authors: Meng S, Li L, Zhou M, Jiang W, Niu H, Yang K Abstract Tumor-infiltrating lymphocytes are associated with the response to neoadjuvent chemotherapy and prognosis in breast cancer. However, the distribution, interaction and prognostic value of tumor‑infiltrating T cells, the main component of the tumor microenvironment, have seldom been reported. In the present study, surgical specimens of 72 breast cancer patients were analyzed. Tumor‑infiltrating T cell subsets [cluster of differen...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
AbstractIn recent years, there has been an emphasis on personalizing breast cancer treatment in order to avoid the debilitating side effects caused by broad-spectrum chemotherapeutic drug treatment. Development of personalized medicine requires the identification of proteins that are expressed by individual tumors. Herein, we reveal the identity of plasma membrane proteins that are overexpressed in estrogen receptor α-positive, HER2-positive, and triple negative breast cancer cells. The proteins we identified are involved in maintaining protein structure, intracellular homeostasis, and cellular architecture; enhancin...
Source: Clinical Proteomics - Category: Biochemistry Source Type: research
Condition:   HER2-Positive Early Breast Cancer Interventions:   Drug: Pertuzumab and Trastuzumab FDC SC;   Drug: Pertuzumab IV;   Drug: Trastuzumab IV Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Dysregulation of cell division resulting in aberrant cell proliferation is a key hallmark of cancer, making it a rational and important target for innovative anti-cancer drug development. Three selective CDK4/6 inhibitors are FDA and EMEA approved for hormone receptor positive/HER2 negative advanced breast cancer. A major emerging appreciation is that these inhibitors are not only cytostatic, but also play critical roles in the interaction between tumour cells and the host immune response. However, to trigger an effective immune response, lymphocytes must also proliferate. This review aims to assimilate o...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract HER2 is a member of epidermal factor receptor (EGFR) family which is overexpressed in breast cancer, ovarian cancer and gastric cancer. Development of new binders for cancer cell surface receptors and expressing them at the surface of exosomes would be a great approach in targeted cancer therapy. We found a high affinity scFv against HER2 using ribosome display with the approach of applying it as a targeting moiety at the surface of exosomes by fusion to lysosomal associated membrane protein 2B (LAMP2B). We also provide some structural information about the ribosome display selected scFv (scFv HFS2) throu...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
rota Nowak Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR), which expression is frequently elevated in TNBC. Inhibitors of these receptors used as monotherapy are often ineffective. Due to that, we studied the efficacy of combined therapy targeting MET and EGFR simultaneously. Two TNBC cell lines were treated with lapatini...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Condition:   Breast Cancer Interventions:   Drug: Ribociclib Placebo;   Drug: Ribociclib;   Drug: NSAI: Letrozole or Anastrazole;   Drug: Letrozole;   Drug: Goserelin Sponsor:   Novartis Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brazil Health | Breast Cancer | Cancer | Cancer & Oncology | Chia | Genetics | HER2 | Hormones | Laboratory Medicine | Study | Women